

CITATION REPORT

List of articles citing

Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection

DOI: 10.1016/j.medj.2021.02.001
Med, 2021, 2, 281-295.e4.

Source: <https://exaly.com/paper-pdf/79546979/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
118	SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation. 2021 , 10, e1306		16
117	Passive Immunity Should and Will Work for COVID-19 for Some Patients. 2021 , 3, 47-68		1
116	SARS-CoV-2 infection: molecular mechanisms of severe outcomes to suggest therapeutics. 2021 , 18, 105-118		2
115	SARS-COV-2, can you be over it?. 2021 , 14, 100514		5
114	Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant. 2021 ,		23
113	Longitudinal characterization of humoral and cellular immunity in hospitalized COVID-19 patients reveal immune persistence up to 9 months after infection.		1
112	Antibody response to SARS-CoV-2 infection over six months among Nicaraguan outpatients. 2021 ,		3
111	A review on the immune responses against novel emerging coronavirus (SARS-CoV-2). 2021 , 69, 213-224		9
110	Discrete immune response signature to SARS-CoV-2 mRNA vaccination versus infection. 2021 ,		6
109	Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. 2021 , 29, 516-521.e3		120
108	The immune response to the novel coronavirus infection. 2021 , 12, 33-40		1
107	SARS-CoV-2-specific memory B cells can persist in the elderly despite loss of neutralising antibodies.		3
106	Population (Antibody) Testing for COVID-19-Technical Challenges, Application and Relevance, an English Perspective. 2021 , 9,		3
105	Disparities in the Evolution of the COVID-19 Pandemic between Spanish Provinces. 2021 , 18,		2
104	Landscape and selection of vaccine epitopes in SARS-CoV-2. 2021 , 13, 101		10
103	Duration of post-COVID-19 symptoms is associated with sustained SARS-CoV-2-specific immune responses. 2021 , 6,		8
102	SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells. 2021 , 12, 4043		53

101	Immunologically relevant aspects of the new COVID-19 vaccines-an GAIA (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paper. 2021 , 30, 1-14	1
100	Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19. 2021 , 19, 155	14
99	Recruitment of highly functional SARS-CoV-2-specific CD8+ T cell receptors mediating cytotoxicity of virus-infected target cells in non-severe COVID-19.	0
98	Insights into the virologic and immunologic features of SARS-COV-2. 2021 , 9, 5007-5018	1
97	Prospective sero surveillance among healthcare workers vaccinated with ChAdOx1 nCoV-19 Corona vaccine in a tertiary hospital of Kerala, India.	0
96	Public awareness about coronavirus vaccine, vaccine acceptance, and hesitancy. 2021 , 93, 6535-6543	18
95	Affinity Tag Coating Enables Reliable Detection of Antigen-Specific B Cells in Immunospot Assays. 2021 , 10,	0
94	Surviving older patients show preserved cellular and humoral immunological memory several months after SARS-CoV-2 infection. 2021 ,	2
93	Long-Term Persistence and Relevant Therapeutic Impact of High-Titer Viral-Neutralizing Antibody in a Convalescent COVID-19 Plasma Super-Donor: A Case Report. 2021 , 12, 690322	
92	Longitudinal analysis of antibody decay in convalescent COVID-19 patients. 2021 , 11, 16796	9
91	The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal. 2021 , 199-225	3
90	. 2021 , 30, 34-47	0
89	A Delay Differential Equation approach to model the COVID-19 pandemic.	1
88	Antibody therapy for COVID-19. 2021 , 21, 553-558	3
87	Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera. 2021 , 9, e0045821	0
86	Advances in understanding the formation and fate of B-cell memory in response to immunisation or infection.	2
85	Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study. 2021 ,	11
84	Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals. 2021 , 131,	20

83	Immunopathology and Immunosenesence, the Immunological Key Words of Severe COVID-19. Is There a Role for Stem Cell Transplantation?. 2021 , 9, 725606	2
82	Immunity to SARS-CoV-2 up to 15 months after infection.	3
81	Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?. 2021 , 9, 1450-1466	31
80	Prime-Boost Vaccination With Covaxin/BBV152 Induces Heightened Systemic Cytokine and Chemokine Responses. 2021 , 12, 752397	3
79	SARS-CoV-2 Reinfection Is a New Challenge for the Effectiveness of Global Vaccination Campaign: A Systematic Review of Cases Reported in Literature. 2021 , 18,	3
78	Long-Term SARS-CoV-2 Specific Immunity Is Affected by the Severity of Initial COVID-19 and Patient Age. 2021 , 10,	0
77	Commercial Interferon-gamma release assay to assess the immune response to first and second doses of mRNA vaccine in previously COVID-19 infected versus uninfected individuals.. 2021 , 115573	3
76	Widely heterogeneous humoral and cellular immunity after mild SARS-CoV-2 infection in a homogeneous population of healthy young men. 2021 , 10, 2141-2150	4
75	Elevated cytokines and chemokines in peripheral blood of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma. 2021 , 17, e1010025	2
74	X-Linked TLR7 Deficiency Underlies Critical COVID-19 Pneumonia in a Male Patient with Ataxia-Telangiectasia. 2021 , 42, 1	7
73	Multiomics Approaches to Understand and Treat COVID-19: Mass Spectrometry and Next-Generation Sequencing. 2021 , 1, 210-237	2
72	Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. 2021 , 13,	0
71	Point-of-Care Diagnostic Tools for Surveillance of SARS-CoV-2 Infections.. 2021 , 9, 766871	1
70	Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.. 2021 , 12, 793953	6
69	SARS-CoV-2-specific memory B cells can persist in the elderly who have lost detectable neutralising antibodies. 2021 ,	6
68	Assessment of the cellular immunity response to the new coronavirus infection COVID-19. 2021 , 20, 10-17	
67	Recruitment of highly cytotoxic CD8 T cell receptors in mild SARS-CoV-2 infection.. 2021 , 110214	1
66	SARS-COV-2 Memory B and T Cells Profile in Mild COVID-19 Convalescents subjects.. 2021 ,	3

65	The changing dynamics of neutralizing antibody response within ten months of SARS-CoV-2 infections.. 2021 ,	1
64	Single-Cell Analysis Reveals the Immune Characteristics of Myeloid Cells and Memory T Cells in Recovered COVID-19 Patients With Different Severities.. 2021 , 12, 781432	1
63	Evaluation of Clinical and Immune Responses in Recovered Children with Mild COVID-19.. 2022 , 14,	0
62	Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges.. 2022 , 13, 140	2
61	Inherited IFNAR1 Deficiency in a Child with Both Critical COVID-19 Pneumonia and Multisystem Inflammatory Syndrome.. 2022 , 1	4
60	Persistence of functional memory B cells recognizing SARS-CoV-2 variants despite loss of specific IgG.. 2021 , 103659	3
59	Immunity to SARS-CoV-2 up to 15 months after infection.. 2022 , 25, 103743	15
58	A Case of Multisystem Inflammatory Syndrome in Adults Following Natural Infection and Subsequent Immunization.. 2021 ,	0
57	Children and Adults With Mild COVID-19: Dynamics of the Memory T Cell Response up to 10 Months.. 2022 , 13, 817876	3
56	Robust and Functional Immune Memory Up to 9 Months After SARS-CoV-2 Infection: A Southeast Asian Longitudinal Cohort.. 2022 , 13, 817905	2
55	Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection.. 2022 , 103, 115659	3
54	SARS-CoV-2 T-cell response in COVID-19 convalescent patients with and without lung sequelae.. 2022 , 8,	
53	A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination.. 2022 , 11, e1380	3
52	SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: a prospective cohort study.. 2021 ,	5
51	SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year.. 2022 , 9, 822316	1
50	Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world.. 2022 , 22, 157	1
49	Progress and Challenges Toward Generation and Maintenance of Long-Lived Memory T Lymphocyte Responses During COVID-19.. 2021 , 12, 804808	1
48	The seroprevalence of COVID-19 in patients living with HIV in metropolitan Detroit.. 2022 , 95646242210766291	

47	Decline of Humoral and Cellular Immune Responses Against SARS-CoV-2 6 Months After Full BNT162b2 Vaccination in Hospital Healthcare Workers.. 2022 , 13, 842912	3
46	Long-term T cell perturbations and waning antibody levels in individuals needing hospitalization for COVID-19.	0
45	Olympic Games in COVID-19 times: lessons learned with special focus on the upcoming FIFA World Cup Qatar 2022.. 2022 ,	3
44	Enhanced SARS-CoV-2-Specific CD4 T Cell Activation and Multifunctionality in Late Convalescent COVID-19 Individuals.. 2022 , 14,	0
43	Characterization of memory T cell subsets and common T-chain cytokines in convalescent COVID-19 individuals.. 2022 ,	2
42	T cell response against SARS-CoV-2 persists after one year in patients surviving severe COVID-19.. 2022 , 78, 103967	3
41	CHARM: COVID-19 Health Action Response for Marines-Association of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 test.. 2022 , 17, e0266691	
40	Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2.. 2022 ,	1
39	The effect of age on the magnitude and longevity of Th1-directed CD4 T cell responses to SARS-CoV-2.. 2022 ,	0
38	Spatio-Temporal Modeling of Immune Response to SARS-CoV-2 Infection. 2021 , 9, 3274	1
37	Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2.	1
36	CHARM: COVID-19 Health Action Response for Marines Association of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 test.	
35	Clonal diversity determines persistence of SARS-CoV-2 epitope-specific T cell response.	
34	Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine.. 2022 , 12, 6687	1
33	COVID-19, Immunity and Pre-Diabetes: Are We Missing Another Target Area to Be Explored?. 2022 , 22, 154-157	
32	Serosurveillance among healthcare workers vaccinated with ChAdOx1 nCoV-19 Corona vaccine in a tertiary hospital of Kerala, India: prospective cohort study	
31	Immunouniverse of SARS-CoV-2.. 2022 , 1-39	0
30	Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant.. 2022 , 13, 2670	8

29	SARS-CoV-2 infection in patients with inborn errors of immunity due to DNA repair defects. 2022 ,	o
28	Research Progress of SARS-CoV-2 Omicron Variant. 2022 , 11, 49-60	
27	Performance of Whole Blood Stimulation Assays for the Quantification of SARS-CoV-2 Specific T-Cell Response: A Cross-Sectional Study. 2022 , 12, 1509	o
26	ORFeome Phage Display Reveals a Major Immunogenic Epitope on the S2 Subdomain of SARS-CoV-2 Spike Protein. 2022 , 14, 1326	o
25	mRNA BNT162b Vaccine Elicited Higher Antibody and CD4+ T-Cell Responses than Patients with Mild COVID-19. 2022 , 10, 1250	1
24	SARS-CoV-2 Specific Antibody Response and T Cell-Immunity in Immunocompromised Patients up to Six Months Post COVID: A Pilot Study. 2022 , 11, 3535	o
23	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. 13,	1
22	Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences. 2022 , 10, 1068	o
21	An additional dose of viral vector COVID -19 vaccine and mRNA COVID -19 vaccine in kidney transplant recipients: a randomized controlled trial (CVIM 4 study).	o
20	SARS-CoV-2-Specific Memory B Cell Responses Are Maintained After Recovery from Natural Infection and Postvaccination.	o
19	Robust humoral and cellular immune responses in long-term convalescent COVID-19 individuals following one-dose SARS-CoV-2 inactivated vaccination. 13,	
18	T cell perturbations persist for at least 6 months following hospitalization for COVID-19. 13,	o
17	Impact of SARS-CoV-2-specific memory B cells on the immune response after mRNA-based Comirnaty vaccine in seronegative health care workers. 13,	o
16	Concordance of SARS-CoV-2 Antibody Results during a Period of Low Prevalence.	o
15	Comparison of the Immune Responses to COVID-19 Vaccines in Bangladeshi Population. 2022 , 10, 1498	o
14	SARS-CoV-2 The Role of Natural Immunity: A Narrative Review. 2022 , 11, 6272	1
13	Healthcare Worker Study Cohort to Determine the Level and Durability of Cellular and Humoral Immune Responses after Two Doses of SARS-CoV-2 Vaccination. 2022 , 10, 1784	o
12	Proinflammatory Innate Cytokines and Distinct Metabolomic Signatures Shape the T Cell Response in Active COVID-19. 2022 , 10, 1762	o

- 11 SARS-CoV-2 specific antibody trajectories in mothers and infants over two months following maternal infection. 13, ○
- 10 Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. **2022**, 50, 1643-1658 ○
- 9 Clonal diversity predicts persistence of SARS-CoV-2 epitope-specific T-cell response. **2022**, 5, ○
- 8 Tissue injury and leukocyte changes in post-acute sequelae of SARS-CoV-2: review of 2833 post-acute patient outcomes per immune dysregulation and microbial translocation in long COVID. 1
- 7 Persistent humoral and CD4+ TH cell immunity after mild SARS-COV-2 infectionThe CoNAN long-term study. 13, ○
- 6 Dynamics of SARS-CoV-2 Antibody Responses up to 9 Months Post-Vaccination in Individuals with Previous SARS-CoV-2 Infection Receiving Inactivated Vaccines. **2023**, 15, 917 ○
- 5 Study of some immunological signatures and their association with COVID-19 in a sample of recovered Iraqi patients. **2023**, 228, 152348 ○
- 4 Employing T-Cell Memory to Effectively Target SARS-CoV-2. **2023**, 12, 301 ○
- 3 COVID-19 adenoviral vector vaccination elicits a robust memory B cell response with the capacity to recognize Omicron BA.2 and BA.5 variants. ○
- 2 Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1. **2023**, 33, 100762 ○
- 1 Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages. ○